Supply of a lutetium-177 PSMA radioligand therapy medicine

Summary

The tender covers the needs-based supply of a European Union-authorised radioligand therapy medicine based on lutetium-177 and binding to PSMA, or an equivalent medicine, for the University Hospital’s Department of Nuclear Medicine and Endocrinology in Salzburg. A 36-month framework agreement will be concluded with one supplier. The estimated requirement is 175 treatment administrations, and the framework agreement has a maximum value of EUR 2,990,000. The award weighting is 60% for price and 40% for quality and functionality. Tenders must be submitted electronically, and electronic invoicing is required during contract performance. Check the tender documents for the precise exclusion grounds, qualification criteria and compliance requirements.